BiotechTube

MEDI7352 + Placebo

Phase 1Completed
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Painful Osteoarthritis of the Knee

Conditions

Painful Osteoarthritis of the Knee

Trial Timeline

Apr 20, 2021 → Dec 2, 2021

NCT ID
NCT04770428

About MEDI7352 + Placebo

MEDI7352 + Placebo is a phase 1 stage product being developed by AstraZeneca for Painful Osteoarthritis of the Knee. The current trial status is completed. This product is registered under clinical trial identifier NCT04770428. Target conditions include Painful Osteoarthritis of the Knee.

What happened to similar drugs?

7 of 20 similar drugs in Painful Osteoarthritis of the Knee were approved

Approved (7) Terminated (2) Active (11)
✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
✅Qutenza + PregabalinAstellas PharmaApproved
✅duloxetine hydrochlorideEli LillyApproved
✅duloxetine hydrochloride + pregabalin + gabapentinEli LillyApproved
✅pregabalinPfizerApproved
✅PregabalinPfizerApproved
✅PregabalinPfizerApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04770428Phase 1Completed

Competing Products

20 competing products in Painful Osteoarthritis of the Knee

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
44
ASP3662 + pregabalin + ASP3662 placebo + pregabalin placeboAstellas PharmaPhase 2
27
QUTENZAAstellas PharmaPhase 3
40
Qutenza + PregabalinAstellas PharmaApproved
43
duloxetine hydrochlorideEli LillyApproved
43
Duloxetine hydrochloride + placeboEli LillyPhase 3
40
Duloxetine + PlaceboEli LillyPhase 3
40
duloxetine hydrochloride + pregabalin + gabapentinEli LillyApproved
43
Duloxetine + Pregabalin + PlaceboEli LillyPhase 3
40
Placebo + Pregabalin + LY545694 21 mg + LY545694 49 mg + LY545694 105 mgEli LillyPhase 2
35
GRC 17356 + Matching PlaceboGlenmark PharmaceuticalsPhase 2
35
GRC 17536 (Medium Dose) + GRC 17536 (Low Dose) + PlaceboGlenmark PharmaceuticalsPhase 2
27
Tapentadol extended release (ER) + Oxycodone controlled release (CR)Johnson & JohnsonPhase 3
32
AZD5213 + pregabalin + Placebo + pregabalin capsulesAstraZenecaPhase 2
35
MEDI7352AstraZenecaPhase 2
27
MEDI7352AstraZenecaPhase 2
35
MK-6096 + PlaceboMerckPhase 2
35
Comparator: A: Pregabalin + Comparator: B: Duloxetine + Comparator: C: Diphenhydramine hydrochlorideMerckPhase 2
27
EMA401 + PlaceboNovartisPhase 2
27
PregabalinPfizerPhase 3
40